Alzheon secures $100m to advance Alzheimer’s disease treatment

13 Jun 2024
·
Deals
www.pharmaceutical-technology.com
Phase 2Phase 3NDA
Alzheon secures $100m to advance Alzheimer’s disease treatment
Preview
Source: Pharmaceutical Technology
The asset demonstrated clinical efficacy in the highest-risk AD population and favourable safety. Credit: PRPicturesProduction / Shutterstock.
Clinical-stage biopharmaceutical company Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801/Valiltramiprosate, an oral tablet designed as a disease-modifying therapy for Alzheimer’s disease (AD).
Recommended Buyer's Guides
Alzheon secures $100m to advance Alzheimer’s disease treatment
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
Alzheon secures $100m to advance Alzheimer’s disease treatment
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry
Alerce Medical Technology Partners spearheaded the financing round.
The development comes after the company raised $50m in a Series D round in 2022.
The investment will be used to complete the APOLLOE4 Phase III clinical trial to evaluate the efficacy of ALZ-801 in 325 early AD patients.
The study will report its results in the third quarter of 2024, with a new drug application (NDA) submission to follow.
Alzheon secures $100m to advance Alzheimer’s disease treatment
Preview
Source: Pharmaceutical Technology
PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Alzheon secures $100m to advance Alzheimer’s disease treatment
Preview
Source: Pharmaceutical Technology
ALZ-801 inhibits the formation of soluble toxic amyloid aggregates, acting upstream from all late-stage amyloid-targeting treatments.
The financial boost will also support the manufacture of the product and prepare for the potential launch of ALZ-801 commercially, as the first oral disease-modifying therapy for Alzheimer’s.
ALZ-801 has demonstrated the ability to fully block the formation of neurotoxic soluble beta-amyloid oligomers at the Phase III clinical dose level.
It also demonstrated clinical efficacy in the highest-risk AD population and favourable safety, without causing higher brain vasogenic oedema risk.
ALZ-801 was also evaluated in a two-year, 84-patient, Phase II biomarker study completed in the second half of 2023.
The biomarker trial is now extending into a fourth year.
Alzheon founder, president and CEO Martin Tolar stated: “Alzheon has experienced tremendous progress in the past year and the promise of our novel oral Alzheimer’s treatment, ALZ-801, has attracted prominent institutional and private investors.
“Our ability to raise $150m over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology.
“Our well-differentiated drug candidate with a favourable safety profile, showing no increased risk of vasogenic brain oedema in more than 3,000 AD patients, is positioned to potentially become the first oral disease-modifying therapy for the treatment of Alzheimer’s disease.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.